Preconception thyroid function optimization and pregnancy outcomes in women with recurrent pregnancy loss: a real-world cohort study
Endocrine Connections · 01.07.2026 · 15 (7)
DOI: 10.1530/ec-26-0215 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Endocrine Connections, online erschienen am 07.07.2026. Verfasst von Heze Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University , Shenyang, Liaoning Province, China. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The management of subclinical hypothyroidism with thyroid-stimulating hormone (TSH) levels between 2.5 and 4.0 mIU/L in women with recurrent pregnancy loss (RPL) remains controversial, as guidelines derived from general populations conflict. While a recent randomized trial confirmed the benefit of initiating levothyroxine (LT4) during early pregnancy, whether a more proactive strategy of preconception thyroid optimization improves outcomes in this high-risk group remains unknown.
Methods
We conducted a retrospective cohort analysis of 896 women with RPL and elevated TSH (2.5–4.0 mIU/L) during pre-pregnancy, from the Recurrent Pregnancy Loss Cohort Study. Based on clinical records, participants were categorized into two groups: treated group (n = 636) and untreated group (n = 260). The primary outcome was miscarriage. Associations were assessed using Firth’s penalized-likelihood regression to address small-sample bias, with propensity score matching as a sensitivity analysis.
Results
After adjustment for antiphospholipid syndrome, degree of education, gravidity, and parity, LT4 treatment was associated with a significantly lower risk of miscarriage (adjusted odds ratio (aOR) = 0.33; 95% CI: 0.20, 0.54; P < 0.001). A reduced risk was also observed for threatened abortion (aOR = 0.49; 95% CI: 0.35, 0.71; P < 0.001). Results were robust in the propensity score-matched analysis.
Conclusion
In women with RPL and elevated TSH (2.5–4.0 mIU/L), a clinical care pathway involving preconception LT4 treatment was significantly associated with a reduced risk of miscarriage. This finding provides real-world evidence supporting the potential value of proactive preconception thyroid optimization in RPL, highlighting it as a priority strategy worthy of prospective investigation versus post-conception treatment initiation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University , Shenyang, Liaoning Province, China.
- Key Laboratory of Maternal-Fetal Medicine of Liaoning Province , Shenyang, Liaoning, China.
- Research Center of China Medical University Birth Cohort , Shenyang, Liaoning Province, China.
ORCID-Profile: Heze Xu
Zitieren
APA
Xu, H., Wang, Z., Liu, Y., Xing, S., Zhen, H., Li, J., & Qiao, C. (2026). Preconception thyroid function optimization and pregnancy outcomes in women with recurrent pregnancy loss: a real-world cohort study. Endocrine Connections, 15(7). https://doi.org/10.1530/ec-26-0215
Vancouver
Xu H, Wang Z, Liu Y, Xing S, Zhen H, Li J, et al. Preconception thyroid function optimization and pregnancy outcomes in women with recurrent pregnancy loss: a real-world cohort study. Endocrine Connections. 2026;15(7). doi:10.1530/ec-26-0215
BibTeX
@article{Xu2026,
author = {Xu, Heze and Wang, Zhijiao and Liu, Yijia and Xing, Shanwei and Zhen, Hang and Li, Jiapo and Qiao, Chong},
title = {Preconception thyroid function optimization and pregnancy outcomes in women with recurrent pregnancy loss: a real-world cohort study},
journal = {Endocrine Connections},
year = {2026},
volume = {15},
number = {7},
doi = {10.1530/ec-26-0215}
}
EUVIMED